Page last updated: 2024-09-04

glucagon and liraglutide

glucagon has been researched along with liraglutide in 71 studies

Compound Research Comparison

Studies (glucagon)	Trials (glucagon)	Recent Studies (post-2010) (glucagon)	Studies (liraglutide)	Trials (liraglutide)	Recent Studies (post-2010) (liraglutide)
26,039	1,498	3,054	2,404	481	2,154

Protein Interaction Comparison

Protein	Taxonomy	glucagon (IC50)	liraglutide (IC50)
Glucagon-like peptide 1 receptor	Homo sapiens (human)		0.0024

Research

Studies (71)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	22 (30.99)	29.6817
2010's	40 (56.34)	24.3611
2020's	9 (12.68)	2.80

Authors

Authors	Studies
Fledelius, C; Knudsen, LB; Larsen, PJ; Tang-Christensen, M	1
Frandsen, U; Heller, RS; Klein, T; Serup, P	1
Agersø, H; Hollingdal, M; Jakobsen, G; Juhl, CB; Pørksen, N; Schmitz, O; Sturis, J; Veldhuis, J	1
Agersø, H; Elbrønd, B; Jensen, LB; Rolan, P; Zdravkovic, M	1
Agersø, H; Elbrønd, B; Hatorp, V; Jakobsen, G; Jensen, LB; Larsen, S; Rolan, P; Sturis, J; Zdravkovic, M	1
Carr, RD; Deacon, CF; Gotfredsen, CF; Knudsen, LB; Larsen, MO; Rolin, B; Wilken, M	1
Carr, RD; Deacon, CF; Knudsen, LB; Larsen, MO; Ribel, U; Rolin, B; Sturis, J; Westergaard, L; Wilken, M	1
Mark, M	1
Agersø, H; Vicini, P	1
An, B; Bloem, CJ; Chang, AM; Galecki, A; Halter, JB; Jakobsen, G; Smith, MJ; Sturis, J	1
Bock, T; Buschard, K; Pakkenberg, B	1
Rachman, J	1
Brock, B; Chandramouli, V; Degn, KB; Jakobsen, G; Juhl, CB; Landau, BR; Rungby, J; Schmitz, O; Sturis, J	1
Holst, JJ	1
Jakobsen, G; Madsbad, S; Matthews, DR; Ranstam, J; Schmitz, O	1
Edwards, CM	1
Astrup, A; Harder, H; Nielsen, L; Tu, DT	1
Joy, SV; Rodgers, PT; Scates, AC	1
Blume, N; Bregenholt, S; Karlsen, AE; Knudsen, LB; Møldrup, A; Nissen Friedrichsen, B; Petersen, JS; Tornhave, D	1
An, B; Feinglos, MN; Pi-Sunyer, FX; Saad, MF; Santiago, O	1
Beruto, V; Di Girolamo, G; González, C; Keller, G; Santoro, S	1
Scheen, AJ	1
Svec, F	1
Garber, AJ	1
Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME	4
Knudsen, LB	1
Hashimoto, N; Hirota, Y; Matsuda, T; Nakamura, T; Ogawa, W; Sakaguchi, K; Seino, S; Takabe, M	1
Coester, HV; Forst, T; Hincelin-Méry, A; Kapitza, C; Poitiers, F; Ruus, P	1
Novikova, L; Robbins, DC; Schwasinger-Schmidt, T; Stehno-Bittel, L; Williams, SJ	1
Breitschaft, A; Darstein, C; Golor, G; Hermosillo Reséndiz, K; Hu, K	1
Elbarsha, AM; Elmehdawi, RR	1
Bardram, L; Calatayud, D; Heller, RS; Hvelplund, A; Kaastrup, P; Kirk, RK; Knudsen, LB; Pyke, C; Reedtz-Runge, S; Ørskov, C	1
Daich, E; Shehadeh, N; Zuckerman-Levin, N	1
Basu, A; Basu, R; Brett, J; Johnson, C; Joyner, M; Nandy, D; Svendsen, CB	1
Hamamoto, S; Hashiramoto, M; Hirukawa, H; Kaku, K; Kaneto, H; Kimura, T; Kohara, K; Okauchi, S; Shimoda, M; Tawaramoto, K	1
Adin, CA; Borin-Crivellenti, S; Gilor, C; Hall, MJ; Lakritz, J; Rajala-Schultz, P; Rudinsky, AJ	1
Cubelo, A; Dorfman, MD; Fischer, JD; Kumar, MR; Matsen, ME; Meek, TH; Morton, GJ; Taborsky, GJ	1
Christiansen, E; Deller, S; Heller, SR; Jensen, L; Korsatko, S; Madsen, J; Pieber, TR	1
Choi, H; Connelly, PW; Kramer, CK; Retnakaran, R; Zinman, B	2
Gupta, Y; Kalra, S	1
Kramer, CK; Retnakaran, R; Zinman, B	1
Flint, A; Ingwersen, SH; Jacobsen, LV; Olsen, AK	1
Adams-Huet, B; Dimitrov, I; Harrison, LB; Hulsey, K; Jaster, AW; Lenkinski, RE; Li, X; Lingvay, I; Pedrosa, I; Pinho, DF; Pop, LM; Vanderheiden, A; Warshauer, JT; Yokoo, T; Yuan, Q	1
Cantwell, M; Heptulla, RA; Ilkowitz, JT; Katikaneni, R; Ramchandani, N	1
Batra, M; Bellini, N; Chaudhuri, A; Dandona, P; Dhindsa, S; Ghanim, H; Green, K; Hejna, J; Kuhadiya, ND; Makdissi, A; Mehta, A; Sandhu, S; Yang, M	1
Ceriello, A; Genovese, S; Gronda, E; Mannucci, E	1
Baranov, O; Deacon, CF; Holst, JJ; Kahle, M; Nauck, MA	1
Ahrén, B; Eto, T; Irie, S; Kurose, T; Kuwata, H; Murotani, K; Seino, S; Seino, Y; Shiramoto, M; Yabe, D	1
Abuaysheh, S; Batra, M; Chaudhuri, A; Dandona, P; Garg, M; Ghanim, H; Green, K; Hejna, J; Kuhadiya, ND; Makdissi, A; Torre, B	1
Bjourson, AJ; Flatt, PR; Gault, VA; Millar, P; Moffett, RC; O'Kane, M; Parthsarathy, V; Pathak, N; Pathak, V	1
Alejandro, R; Baidal, D; Gil, AA; Lagari, V; Mantero, A; Messinger, S; Padilla, N; Peixoto, E; Ricordi, C; Vendrame, F	1
Carria, L; Cengiz, E; Galderisi, A; Sherr, J; Tamborlane, W; Tichy, E; VanName, M; Weinzimer, S; Weyman, K; Zgorski, M	1
Chen, J; Feng, S; Hu, L; Liang, M; Luan, X; Shen, J; Wang, X; Xu, X	1
Eckel, RH; Koh, KK; Lim, S	1
Heinla, I; Jagomäe, T; Koppel, T; Pallase, M; Plaas, M; Seppa, K; Terasmaa, A; Toots, M; Vasar, E	1
Jakupović, L; Javor, E; Lucijanić, M; Lucijanić, T; Rahelić, D; Skelin, M	1
Bonner, C; Bousquet, C; Coddeville, A; Daoudi, M; Delalleau, N; Gmyr, V; Hubert, T; Kerr-Conte, J; Martineau, Y; Moerman, E; Pasquetti, G; Pattou, F; Quenon, A; Saponaro, C; Staels, B; Thévenet, J; Vantyghem, MC	1
Brooks, A; Guyton, J; Jeon, M	1
Meng, S; Pesavento, TE; Singh, P; Taufeeq, M; Walsh, D; Washburn, K	1
Flatt, PR; Irwin, N; Moffett, RC; Tanday, N	1
Fujiwara, Y; Hamamoto, Y; Haraguchi, T; Ishitobi, M; Kubota, S; Kubota-Okamoto, S; Kurose, T; Kuwata, H; Murotani, K; Seino, Y; Usui, R; Yabe, D; Yamada, Y; Yamazaki, Y	1
Ai, M; Aviello, G; Boudjadja, MB; Coskun, T; Costa, A; Culotta, I; D'Agostino, G; Emmerson, PJ; Hodson, DJ; Hunter, J; Luckman, SM; Nunn, N; Snider, BM; Valencia-Torres, L	1
Flatt, PR; Irwin, N; Lafferty, RA; Tanday, N	1
Bojsen-Møller, KN; Deacon, CF; Hansen, AE; Hansen, ML; Holst, JJ; Johannesen, HH; Keller, SH; Kjaer, A; Klausen, TL; Löfgren, J; Loft, A; Madsbad, S; Martinussen, C; Svane, MS; Wewer Albrechtsen, NJ	1
Abdelaal, M; Docherty, NG; Elliott, JA; Flatt, PR; Khan, D; Le Roux, CW; Moffett, CR; Naughton, V; Sridhar, A	1
Frikke-Schmidt, R; Holst, JJ; Janus, C; Jensen, SBK; Juhl, CR; Knudsen, C; Lundgren, JR; Madsbad, S; Martinussen, C; Stallknecht, BM; Torekov, SS; Wiingaard, C	1
Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K	1

Reviews

14 review(s) available for glucagon and liraglutide

Article	Year
NN-2211 Novo Nordisk. IDrugs : the investigational drugs journal, 2003, Volume: 6, Issue:3 Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Liraglutide; Technology, Pharmaceutical	2003
Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2004, Volume: 21 Suppl 1 Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptide Fragments; Peptides; Protein Precursors; Venoms	2004
Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert opinion on emerging drugs, 2004, Volume: 9, Issue:1 Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Afferent Pathways; Animals; Appetite; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Hypothalamus; Insulin; Insulin Secretion; Intestinal Mucosa; Islets of Langerhans; Liraglutide; Lizards; Maleimides; Mice; Mice, Knockout; Mice, Obese; Peptide Fragments; Peptides; Proglucagon; Protein Precursors; Rats; Rats, Zucker; Receptors, Glucagon; Venoms	2004
Incretin mimetics as emerging treatments for type 2 diabetes. The Annals of pharmacotherapy, 2005, Volume: 39, Issue:1 Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptide Fragments; Peptides; Protein Precursors; Venoms	2005
Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:8 Topics: Animals; Blood Glucose; Body Weight; Cell Proliferation; Diabetes Mellitus, Type 2; Drugs, Investigational; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liraglutide; Peptides; Randomized Controlled Trials as Topic; Venoms	2006
Incretin physiology and its role in type 2 diabetes mellitus. The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:7 Suppl 7 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms	2010
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. The American journal of managed care, 2010, Volume: 16, Issue:7 Suppl Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
Liraglutide: the therapeutic promise from animal models. International journal of clinical practice. Supplement, 2010, Issue:167 Topics: Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liraglutide; Mice; Mice, Obese; Peptides; Rats; Rats, Zucker; Receptors, Glucagon; Swine; Swine, Miniature; Venoms	2010
Can GLP-1 preparations be used in children and adolescents with diabetes mellitus? Pediatric endocrinology reviews : PER, 2014, Volume: 11, Issue:3 Topics: Adolescent; Adult; Child; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Male; Pediatric Obesity; Randomized Controlled Trials as Topic; Receptors, Glucagon	2014
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics. Clinical pharmacokinetics, 2016, Volume: 55, Issue:6 Topics: Area Under Curve; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Interactions; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Lipids; Liraglutide; Liver Failure; Renal Insufficiency; Sex Factors	2016
Glucagon and heart in type 2 diabetes: new perspectives. Cardiovascular diabetology, 2016, 08-27, Volume: 15, Issue:1 Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucosides; Heart; Heart Failure; Humans; Hypoglycemic Agents; Liraglutide; Myocardium; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2016
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. Atherosclerosis, 2018, Volume: 272 Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2018
The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients. International journal of clinical practice, 2018, Volume: 72, Issue:12 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide	2018
Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019, Oct-15, Volume: 76, Issue:21 Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Exenatide; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Treatment Outcome; Weight Loss	2019

Trials

22 trial(s) available for glucagon and liraglutide

Article	Year
Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes, 2002, Volume: 51, Issue:2 Topics: Aged; Blood Glucose; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Homeostasis; Humans; Insulin; Insulin Secretion; Liraglutide; Male; Middle Aged; Osmolar Concentration; Postprandial Period	2002
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia, 2002, Volume: 45, Issue:2 Topics: Adolescent; Adult; Area Under Curve; Blood Glucose; Dose-Response Relationship, Drug; Double-Blind Method; Glucagon; Glucagon-Like Peptide 1; Humans; Liraglutide; Male; Middle Aged; Peptide Fragments; Placebos; Protein Precursors; Reference Values; Safety	2002
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes care, 2002, Volume: 25, Issue:8 Topics: Adolescent; Adult; Blood Glucose; Double-Blind Method; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Middle Aged	2002
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2003, Volume: 19, Issue:2-3 Topics: Adult; Blood Glucose; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Liraglutide; Male; Nonlinear Dynamics; Peptide Fragments; Protein Precursors	2003
The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes, 2003, Volume: 52, Issue:7 Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Liraglutide; Male; Middle Aged; Peptide Fragments; Placebos; Protein Precursors; Reference Values	2003
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes, 2004, Volume: 53, Issue:5 Topics: Circadian Rhythm; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucose; Hormones; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Liraglutide; Male; Middle Aged	2004
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes care, 2004, Volume: 27, Issue:6 Topics: Blood Glucose; Body Weight; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Insulin; Liraglutide; Male; Middle Aged; Placebos; Treatment Outcome	2004
The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes care, 2004, Volume: 27, Issue:8 Topics: Blood Glucose; Body Composition; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Liraglutide; Male; Middle Aged; Placebos	2004
Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:8 Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged	2005
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:7 Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Resistance; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Metformin; Middle Aged; Peptides	2013
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes research and clinical practice, 2014, Volume: 103, Issue:3 Topics: Adamantane; Adolescent; Adult; Blood Glucose; Cyclohexanes; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Healthy Volunteers; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Prognosis; Pyrrolidines; Somatostatin; Vildagliptin; Young Adult	2014
The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diabetes & vascular disease research, 2014, Volume: 11, Issue:6 Topics: Acetylcholine; Aged; Blood Glucose; Blood Pressure; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Lipids; Liraglutide; Male; Middle Aged; Nitroprusside; Plethysmography	2014
Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:8 Topics: Adult; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Middle Aged	2015
The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:10 Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Middle Aged; Treatment Outcome	2015
Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. The Journal of clinical endocrinology and metabolism, 2016, Volume: 101, Issue:4 Topics: Adipose Tissue; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Liraglutide; Magnetic Resonance Imaging; Male; Middle Aged	2016
Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial. Journal of diabetes science and technology, 2016, Volume: 10, Issue:5 Topics: Adult; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Female; Glucagon; Humans; Hyperglycemia; Hypoglycemic Agents; Incidence; Insulin; Insulin Infusion Systems; Liraglutide; Male; Middle Aged; ROC Curve	2016
Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks. Diabetes care, 2016, Volume: 39, Issue:6 Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Middle Aged; Obesity; Overweight; Postprandial Period; Time Factors; Treatment Outcome	2016
Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:2 Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome	2017
Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial. Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:3 Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Epinephrine; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose Clamp Technique; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Japan; Linagliptin; Liraglutide; Male; Middle Aged; Norepinephrine	2017
Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes. Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:9 Topics: Adult; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Ghrelin; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Infusion Systems; Ketone Bodies; Lipolysis; Liraglutide; Male; Middle Aged	2017
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. The Journal of clinical endocrinology and metabolism, 2018, 03-01, Volume: 103, Issue:3 Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Female; Glucagon; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Islet Amyloid Polypeptide; Liraglutide; Male; Meals; Postprandial Period; Treatment Outcome; Young Adult	2018
Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function. Obesity (Silver Spring, Md.), 2023, Volume: 31, Issue:4 Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise; Glucagon; Glucose; Humans; Hypoglycemic Agents; Liraglutide; Weight Loss	2023

Other Studies

35 other study(ies) available for glucagon and liraglutide

Article	Year
Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes, 2001, Volume: 50, Issue:11 Topics: Animals; Blood Glucose; Body Weight; Defecation; Diuresis; Dose-Response Relationship, Drug; Drinking; Drug Administration Schedule; Eating; Energy Metabolism; Feeding Behavior; Glucagon; Glucagon-Like Peptide 1; Lipids; Liraglutide; Male; Obesity; Peptide Fragments; Protein Precursors; Rats; Rats, Wistar; Reference Values; Time Factors	2001
IMPAN cells: a pancreatic model for differentiation into endocrine cells. Archives of biochemistry and biophysics, 2001, Nov-15, Volume: 395, Issue:2 Topics: Activins; Animals; Basic Helix-Loop-Helix Transcription Factors; Cattle; Cell Differentiation; Cell Line; Collagen; Collagen Type I; Endocrine Glands; Glucagon; Glucagon-Like Peptide 1; Homeodomain Proteins; Inhibin-beta Subunits; Insulin; Liraglutide; Mice; Mice, Transgenic; Nerve Tissue Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stem Cells; Temperature; Trans-Activators	2001
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. American journal of physiology. Endocrinology and metabolism, 2002, Volume: 283, Issue:4 Topics: Animals; Blood Glucose; Body Weight; Cell Division; Diabetes Mellitus, Type 2; Eating; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Hyperglycemia; Insulin; Islets of Langerhans; Liraglutide; Mice; Mice, Inbred C57BL; Mice, Obese; Peptide Fragments; Peptides; Protein Precursors; Venoms	2002
NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. European journal of pharmacology, 2002, Sep-13, Volume: 451, Issue:2 Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Hypoglycemic Agents; Insulin; Liraglutide; Male; Peptide Fragments; Protein Precursors; Swine, Miniature	2002
The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2003, Volume: 111, Issue:12 Topics: Animals; Body Weight; Cell Count; Glucagon; Glucagon-Like Peptide 1; Islets of Langerhans; Liraglutide; Male; Organ Size; Rats; Rats, Sprague-Dawley; Time Factors	2003
GLP-1: target for a new class of antidiabetic agents? Journal of the Royal Society of Medicine, 2004, Volume: 97, Issue:6 Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptide Fragments; Peptides; Protein Precursors; Venoms	2004
The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochemical and biophysical research communications, 2005, May-06, Volume: 330, Issue:2 Topics: Animals; Apoptosis; Cyclic AMP; Cytokines; Fatty Acids, Nonesterified; Glucagon; Glucagon-Like Peptide 1; Islets of Langerhans; Liraglutide; Nitric Oxide; Oxidoreductases; Peptide Fragments; Phosphatidylinositol 3-Kinases; Protein Precursors; Rats; Rats, Wistar; Signal Transduction	2005
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes]. Revue medicale de Liege, 2007, Volume: 62, Issue:4 Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss	2010
Distinguishing among incretin-based therapies. Patient education and self-management. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms	2010
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms	2010
C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment. Diabetes research and clinical practice, 2012, Volume: 98, Issue:3 Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Kinetics; Liraglutide; Male; Middle Aged; Receptors, Glucagon	2012
Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats. Pharmacological research, 2013, Volume: 76 Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liraglutide; Male; Rats; Rats, Zucker	2013
An accidental liraglutide overdose: case report. The Libyan journal of medicine, 2014, Volume: 9, Issue:1 Topics: Accidents; Blood Glucose; Drug Overdose; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Middle Aged; Nausea; Treatment Outcome; Vomiting	2014
GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology, 2014, Volume: 155, Issue:4 Topics: Animals; Antibodies, Monoclonal; Blood Pressure; Body Weight; Cell Line; Cricetinae; Duodenum; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Haplorhini; Heart Rate; Humans; Insulin; Insulin Secretion; Ligands; Liraglutide; Mice; Mice, Inbred C57BL; Mice, Knockout; Peptides; Protein Binding; Receptors, Glucagon; Tissue Distribution; Transfection; Venoms	2014
Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes. Molecular and cellular endocrinology, 2015, Jan-15, Volume: 400 Topics: Animals; Apoptosis; Blood Glucose; Caspases; Cell Proliferation; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Ki-67 Antigen; Liraglutide; Male; Mice; Mice, Transgenic; Organ Size; Pioglitazone; Proto-Oncogene Proteins c-bcl-2; RNA, Ribosomal, 18S; Thiazolidinediones; Time Factors; Triglycerides	2015
Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats. Domestic animal endocrinology, 2015, Volume: 51 Topics: Animals; Appetite; Blood Glucose; Cats; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Clamp Technique; Hyperglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Weight Loss	2015
Evidence That in Uncontrolled Diabetes, Hyperglucagonemia Is Required for Ketosis but Not for Increased Hepatic Glucose Production or Hyperglycemia. Diabetes, 2015, Volume: 64, Issue:7 Topics: Animals; Diabetes Mellitus, Experimental; Forkhead Box Protein O1; Forkhead Transcription Factors; Glucagon; Glucagon-Like Peptide 1; Glucose; Hyperglycemia; Insulin; Ketone Bodies; Ketosis; Liraglutide; Liver; Male; Rats, Wistar; Receptors, Glucagon; Streptozocin	2015
Letter to the Editor: Comment on "The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial" by Kramer C.K., et al. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:11 Topics: Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hypoglycemic Agents; Liraglutide; Male	2015
Response to the Letter by Kalra S. et al. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:11 Topics: Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hypoglycemic Agents; Liraglutide; Male	2015
Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion. The Journal of clinical endocrinology and metabolism, 2017, 08-01, Volume: 102, Issue:8 Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Glucagon; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Liraglutide; Randomized Controlled Trials as Topic	2017
Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice. The Journal of endocrinology, 2017, Volume: 234, Issue:3 Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Interleukin-6; Liraglutide; Male; Mice; Neurons; Neuroprotective Agents	2017
Chronic Liraglutide Administration Fails to Suppress Postprandial Glucagon Levels in Type 1 Diabetic Islet Allograft Recipients With Graft Dysfunction. Transplantation, 2018, Volume: 102, Issue:1 Topics: Diabetes Mellitus, Type 1; Glucagon; Humans; Hypoglycemic Agents; Islets of Langerhans Transplantation; Liraglutide; Postprandial Period	2018
Liraglutide regulates the viability of pancreatic α-cells and pancreatic β-cells through cAMP-PKA signal pathway. Life sciences, 2018, Feb-15, Volume: 195 Topics: Animals; Apoptosis; Cell Line; Cell Survival; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Glucagon; Glucagon-Secreting Cells; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Liraglutide; Mice; MicroRNAs; Signal Transduction	2018
Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome. Scientific reports, 2018, 07-05, Volume: 8, Issue:1 Topics: Animals; Blood Glucose; Calmodulin-Binding Proteins; Disease Models, Animal; Endoplasmic Reticulum Stress; Gene Knockout Techniques; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose Intolerance; Glucose Tolerance Test; Humans; Incretins; Injections, Subcutaneous; Insulin; Islets of Langerhans; Liraglutide; Male; Membrane Proteins; Rats; Rats, Transgenic; Treatment Outcome; Wolfram Syndrome	2018
The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release. Cell reports, 2019, 08-06, Volume: 28, Issue:6 Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Glucagon; Glucosides; Humans; Liraglutide; Male; Mice; Somatostatin	2019
Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study. Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:5 Topics: Adult; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Liraglutide; Organ Transplantation; Recombinant Fusion Proteins; Retrospective Studies	2020
Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetes. The Journal of endocrinology, 2020, Volume: 245, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Blood Glucose; Cell Proliferation; Cell Transdifferentiation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Secreting Cells; Hydrocortisone; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liraglutide; Mice, Inbred C57BL; Mice, Transgenic; Sitagliptin Phosphate	2020
Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study. Journal of diabetes investigation, 2021, Volume: 12, Issue:12 Topics: Adult; Apolipoprotein B-48; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Japan; Liraglutide; Male; Middle Aged; Peptides; Postprandial Period; Prospective Studies; Recombinant Fusion Proteins	2021
Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation. Molecular metabolism, 2022, Volume: 55 Topics: Animals; Appetite; Appetite Depressants; Blood Glucose; Cholecystokinin; Exenatide; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Insulin; Liraglutide; Male; Mice; Mice, Inbred C57BL; Neurons; Receptors, Gastrointestinal Hormone	2022
Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists. Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:12 Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose; Insulin; Liraglutide; Mice; Neuropeptide Y; Neuropeptides; Peptide YY; Streptozocin; Tyrosine	2022
Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight. International journal of obesity (2005), 2022, Volume: 46, Issue:11 Topics: Adult; Alanine; Amino Acids; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Liver; Male; Middle Aged; Overweight	2022
Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats. PloS one, 2022, Volume: 17, Issue:9 Topics: Animals; Blood Glucose; Diabetes Mellitus; Fenofibrate; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Insulin; Liraglutide; Male; Metformin; Obesity; Ramipril; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosuvastatin Calcium; Somatostatin	2022
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:9 Topics: Bupropion; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Humans; Liraglutide; Naltrexone; Obesity; Overweight; Peptides; Proglucagon; Weight Loss	2023